120 related articles for article (PubMed ID: 37752055)
1. [Efficacy, prognosis and influencing factors of transcatheter arterial embolization in the treatment of neuroendocrine neoplasm liver metastases].
Zhang Y; Xu RT; Bai JA; Hu P; Li XY; Tian Y; Tang QY
Zhonghua Yi Xue Za Zhi; 2023 Oct; 103(37):2952-2958. PubMed ID: 37752055
[No Abstract] [Full Text] [Related]
2. Prolonged progression-free survival achieved by octreotide LAR plus transarterial embolization in low-to-intermediate grade neuroendocrine tumor liver metastases with high hepatic tumor burden.
Liu Y; Liu H; Chen W; Yu H; Yao W; Fan W; Li J; Chen M; Chen J; Wang Y
Cancer Med; 2022 Jul; 11(13):2588-2600. PubMed ID: 35289113
[TBL] [Abstract][Full Text] [Related]
3. Transcatheter arterial embolization in patients with neuroendocrine neoplasms related to liver metastasis with different blood supplies.
Bai J; Song J; Zhang Y; Li X; Yan L; Hu P; Tang Q
Cancer Med; 2023 Sep; 12(18):18578-18587. PubMed ID: 37587855
[TBL] [Abstract][Full Text] [Related]
4. Transarterial embolization (TAE) is equally effective and slightly safer than transarterial chemoembolization (TACE) to manage liver metastases in neuroendocrine tumors.
Fiore F; Del Prete M; Franco R; Marotta V; Ramundo V; Marciello F; Di Sarno A; Carratù AC; de Luca di Roseto C; Colao A; Faggiano A
Endocrine; 2014 Sep; 47(1):177-82. PubMed ID: 24385266
[TBL] [Abstract][Full Text] [Related]
5. Outcomes After Transarterial Embolization of Neuroendocrine Tumor Liver Metastases Using Spherical Particles of Different Sizes.
Zener R; Yoon H; Ziv E; Covey A; Brown KT; Sofocleous CT; Thornton RH; Boas FE
Cardiovasc Intervent Radiol; 2019 Apr; 42(4):569-576. PubMed ID: 30627774
[TBL] [Abstract][Full Text] [Related]
6. Embolotherapy for Neuroendocrine Tumor Liver Metastases: Prognostic Factors for Hepatic Progression-Free Survival and Overall Survival.
Chen JX; Rose S; White SB; El-Haddad G; Fidelman N; Yarmohammadi H; Hwang W; Sze DY; Kothary N; Stashek K; Wileyto EP; Salem R; Metz DC; Soulen MC
Cardiovasc Intervent Radiol; 2017 Jan; 40(1):69-80. PubMed ID: 27738818
[TBL] [Abstract][Full Text] [Related]
7. Additional holmium-166 radioembolisation after lutetium-177-dotatate in patients with neuroendocrine tumour liver metastases (HEPAR PLuS): a single-centre, single-arm, open-label, phase 2 study.
Braat AJAT; Bruijnen RCG; van Rooij R; Braat MNGJA; Wessels FJ; van Leeuwaarde RS; van Treijen MJC; de Herder WW; Hofland J; Tesselaar MET; de Jong HWAM; Lam MGEH
Lancet Oncol; 2020 Apr; 21(4):561-570. PubMed ID: 32112737
[TBL] [Abstract][Full Text] [Related]
8. Hepatic intra-arterial therapies in metastatic neuroendocrine tumors: lessons from clinical practice.
Grozinsky-Glasberg S; Kaltsas G; Kaltsatou M; Lev-Cohain N; Klimov A; Vergadis V; Uri I; Bloom AI; Gross DJ
Endocrine; 2018 Jun; 60(3):499-509. PubMed ID: 29383678
[TBL] [Abstract][Full Text] [Related]
9. Phase 1b study of pasireotide, everolimus, and selective internal radioembolization therapy for unresectable neuroendocrine tumors with hepatic metastases.
Kim HS; Shaib WL; Zhang C; Nagaraju GP; Wu C; Alese OB; Chen Z; Brutcher E; Renfroe M; El-Rayes BF
Cancer; 2018 May; 124(9):1992-2000. PubMed ID: 29451701
[TBL] [Abstract][Full Text] [Related]
10. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival.
Gupta S; Johnson MM; Murthy R; Ahrar K; Wallace MJ; Madoff DC; McRae SE; Hicks ME; Rao S; Vauthey JN; Ajani JA; Yao JC
Cancer; 2005 Oct; 104(8):1590-602. PubMed ID: 16134179
[TBL] [Abstract][Full Text] [Related]
11. Transarterial (chemo)embolisation versus no intervention or placebo for liver metastases.
Swierz MJ; Storman D; Riemsma RP; Wolff R; Mitus JW; Pedziwiatr M; Kleijnen J; Bala MM
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD009498. PubMed ID: 32163181
[TBL] [Abstract][Full Text] [Related]
12. DAXX Mutation Status of Embolization-Treated Neuroendocrine Tumors Predicts Shorter Time to Hepatic Progression.
Ziv E; Rice SL; Filtes J; Yarmohammadi H; Boas FE; Erinjeri JP; Petre EN; Brody LA; Brown KT; Covey AM; Getrajdman GI; Maybody M; Raj N; Sofocleous CT; Solomon SB; Reidy-Lagunes D
J Vasc Interv Radiol; 2018 Nov; 29(11):1519-1526. PubMed ID: 30342802
[TBL] [Abstract][Full Text] [Related]
13. Hepatic arterial embolization and chemoembolization for imatinib-resistant gastrointestinal stromal tumors.
Kobayashi K; Szklaruk J; Trent JC; Ensor J; Ahrar K; Wallace MJ; Madoff DC; Murthy R; Hicks ME; Gupta S
Am J Clin Oncol; 2009 Dec; 32(6):574-81. PubMed ID: 19636238
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes of patients with G1/G2 neuroendocrine tumors arising from foregut or hindgut treated with somatostatin analogs: a retrospective study.
Ida H; Honma Y; Hirano H; Shoji H; Iwasa S; Okita N; Takashima A; Kato K; Fukuda T; Boku N
Invest New Drugs; 2019 Jun; 37(3):573-578. PubMed ID: 30267338
[TBL] [Abstract][Full Text] [Related]
15. Treatment of hepatocellular carcinoma with transcatheter arterial embolization. Analysis of prognostic factors.
Taniguchi K; Nakata K; Kato Y; Sato Y; Hamasaki K; Tsuruta S; Nagataki S
Cancer; 1994 Mar; 73(5):1341-5. PubMed ID: 8111699
[TBL] [Abstract][Full Text] [Related]
16. Quantitative Pretreatment CT Parameters as Predictors of Tumor Response of Neuroendocrine Tumor Liver Metastasis to Transcatheter Arterial Bland Embolization.
Liu Y; Chen W; Cui W; Liu H; Zhou X; Chen L; Li J; Chen M; Chen J; Wang Y
Neuroendocrinology; 2020; 110(7-8):697-704. PubMed ID: 31639795
[TBL] [Abstract][Full Text] [Related]
17. [Safety and efficacy of transarterial embolization combined with octreotide LAR on reducing tumor burden for neuroendocrine tumor liver metastasis].
Liu YM; Lian F; Zhou XF; Chen WC; Liu HK; Yao W; Fan WZ; Li JP; Chen J; Wang Y
Zhonghua Yi Xue Za Zhi; 2019 Apr; 99(15):1142-1146. PubMed ID: 31006216
[No Abstract] [Full Text] [Related]
18. Primary tumour resection may improve survival in functional well-differentiated neuroendocrine tumours metastatic to the liver.
Citterio D; Pusceddu S; Facciorusso A; Coppa J; Milione M; Buzzoni R; Bongini M; deBraud F; Mazzaferro V
Eur J Surg Oncol; 2017 Feb; 43(2):380-387. PubMed ID: 27956320
[TBL] [Abstract][Full Text] [Related]
19. Factors affecting periprocedural morbidity and mortality and long-term patient survival after arterial embolization of hepatic neuroendocrine metastases.
Sofocleous CT; Petre EN; Gonen M; Reidy-Lagunes D; Ip IK; Alago W; Covey AM; Erinjeri JP; Brody LA; Maybody M; Thornton RH; Solomon SB; Getrajdman GI; Brown KT
J Vasc Interv Radiol; 2014 Jan; 25(1):22-30; quiz 31. PubMed ID: 24365504
[TBL] [Abstract][Full Text] [Related]
20. Towards new response criteria in neuroendocrine tumors: which changes in MRI parameters are associated with longer progression-free survival after radioembolization of liver metastases?
Ceelen F; Theisen D; de Albéniz XG; Auernhammer CJ; Haug AR; D'Anastasi M; Paprottka PM; Rist C; Reiser MF; Sommer WH
J Magn Reson Imaging; 2015 Feb; 41(2):361-8. PubMed ID: 24446275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
